市場調查報告書
商品編碼
1058819

百日咳疫苗的全球市場(2021年∼2028年)

Global Pertussis Vaccine Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球百日咳疫苗市場相關調查分析,提供市場動態,產業分析,市場分析,競爭情形等系統性資訊。

目錄

第1章 全球百日咳疫苗的市場方法與範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球百日咳疫苗市場-市場定義和概要

第3章 全球百日咳疫苗市場-摘要整理

  • 市場明細:各產品類型
  • 市場明細:各疫苗類型
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 全球百日咳疫苗市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球百日咳疫苗市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 未滿足需求

第6章 全球百日咳疫苗市場-COVID-19分析

  • 市場上的COVID-19分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後的市場方案/未來市場方案
  • COVID-19的價格的動態
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球百日咳疫苗市場:各產品類型

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析(%):各產品類型
  • 市場魅力指數:各產品類型
    • DTaP疫苗*
    • 三種混合疫苗

第8章 全球百日咳疫苗市場:各疫苗類型

  • 簡介
  • 市場規模分析,及與前一年同期比較成長分析(%):各疫苗類型
  • 市場魅力指數:各疫苗類型
    • 全細胞疫苗
    • 無細胞疫苗

第9章 全球百日咳疫苗市場:各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各終端用戶
    • 市場魅力指數:各終端用戶
  • 醫院*
    • 簡介
    • 市場規模分析(100萬美元)(2019年∼2028年),及與前一年同期比較成長分析(%)(2020年∼2028年)
  • 診所
  • 疫苗接種中心
  • 其他

第10章 全球百日咳疫苗市場:各地區

  • 簡介
    • 市場規模分析(100萬美元)(2019年∼2028年),及與前一年同期比較成長分析(%)(2020年∼2028年):各地區
    • 市場魅力指數:各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第11章 全球百日咳疫苗市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準

第12章 全球百日咳疫苗市場-企業簡介概要

  • GlaxoSmithKline*
    • 企業概要
    • 產品系列及說明
    • 主要亮點
    • 財務概要
  • Sanofi
  • Novartis AG
  • Seqirus
  • Merck Sharp & Dohme Corp
  • Astellas Pharma US, Inc.
  • KM Biologics

第13章 全球百日咳疫苗市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH4683

Market Overview

The global pertussis vaccine market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Whooping cough is treated with a pertussis vaccine. This vaccine is only available in conjunction with other vaccines. All children, babies, teenagers, and pregnant women should get vaccinated against pertussis.

Market Dynamics

Various factors such as growth in the adoption of pertussis vaccination are expected to drive the market growth.

The adoption of pertussis vaccination is expected to drive the market growth

Pertussis vaccines help protect babies, children, and adults from whooping cough, a respiratory disease. Uncontrollable, violent coughing fits characterize whooping cough. It can lead to severe complications in babies. To protect against whooping cough, all infants, children, and adults should receive a vaccine. The vaccine protects people, particularly infants, from contracting pertussis. Infants are especially vulnerable to whooping cough. Babies with whooping cough are at risk of developing pneumonia (lung infection), uncontrollable shaking, and even brain damage. Because whooping cough begins with mild, cold-like symptoms, many people are unaware they have the infection. Without vaccination, people can easily spread whooping cough to others during the early stages of infection. The CDC recommends whooping cough vaccination for all infants and children, preteens and teenagers, and pregnant women. Adults who never received a Tdap dose should also be immunized against pertussis.

The increasing advantage of the pertussis vaccine is expected to boost market growth. For instance, on January 15th, 2019, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccines, the FDA approved, are used to include repeat vaccination help protect against tetanus, diphtheria, and pertussis. Sanofi manufactures the vaccine under the brand name Adacel. Hence, the growing adoption of pertussis vaccination among people is expected to drive market growth.

The side effects associated with the pertussis vaccine is expected to hamper the market growth

Vaccines, like all medications, may cause side effects. Most side effects are minor, last only a short time, and do not cause long-term problems. The whooping cough vaccine may cause fever, redness, soreness, or swelling where the injection was given, nausea, headache, tiredness, and aching muscles. Serious side effects are extremely uncommon, including severe allergic reactions. These side effects may be more severe in some people. They may temporarily disrupt daily activities. Three out of every hundred people who received Tdap or Td experienced severe arm swelling. One in every 250 adults who receive the Tdap vaccine develops a 102 degrees Fahrenheit or higher fever.

During Tdap clinical trials, two adults experienced temporary nervous system problems. It's unclear whether the vaccine caused this. Tdap or Td vaccination has resulted in severe arm swelling where the shot was administered in rare cases.

COVID-19 Impact Analysis

According to preliminary data, people who have received vaccines have a lower risk of developing severe diseases. Scientists believe vaccines accomplish this by priming the innate immune response to fight. Recent research has looked into inactivated vaccines, particularly diphtheria, tetanus, and pertussis (DTP) vaccines, to see if previous immunizations result in less severe COVID-19 manifestations. A study published in 2020 looked into the bacterial vaccines DTP and concluded that children's possible protection against SARS-CoV-2 could be attributed to cross-reactivity induced by these vaccinations.

Segment Analysis

By product type, the DTaP vaccine segment is expected to dominate the market growth

Diphtheria, tetanus, and pertussis can be prevented with the DTaP vaccine. Diphtheria and pertussis are contagious diseases that spread from person to person. Tetanus enters the body through open wounds or cuts. Diphtheria is a respiratory disease resulting in difficulty breathing, paralysis, heart failure, and death. It's extremely contagious and spreads through coughing and sneezing. Tetanus, also known as lockjaw, is caused by bacteria commonly found in soil. When it enters the body, it releases a toxin that attacks the nervous system, resulting in muscle spasms and death if not treated. Pertussis, also highly contagious, causes severe coughing spasms that make it difficult for infants to eat, drink, or even breathe. It can cause pneumonia, seizures, brain damage, and death.

Children under the age of seven are eligible for DTaP. Tetanus, diphtheria, and pertussis (Tdap and Td) vaccines are available for older children, adolescents, and adults. Children should receive five doses of DTaP at the ages of two months, four months, six months, 15 to 18 months, and four to six years. DTaP can be administered as a separate vaccine or as part of a combination vaccine (a type of vaccine that combines more than one vaccine into one-shot). DTaP can be given alongside other vaccines. Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis are the seven paediatric DTaP vaccines currently licensed and used in the United States.

Geographical Analysis

North America region is expected to hold the largest market share in the global pertussis vaccine market

The increasing incidence of whooping cough is expected to drive the market growth in the forecast period.

The Centers for Disease Control and Prevention (CDC) reported 48,277 cases of pertussis in the United States. As of 2020, the number of pertussis cases in the United States of America was 18,617, accounting for 29.05 percent of all pertussis cases worldwide. Hence, with the increasing incidence of whooping cough, the demand for pertussis vaccine is expected to drive the market growth in this region.

In the United States, there are two vaccines available to help prevent pertussis. The DTaP is for children under seven, and the Tdap is for older children, teens, and adults. These vaccines are highly recommended, and most children and adolescents get them. In 2017, approximately 83% of children aged 19 to 35 months received the DTaP vaccine.

Competitive Landscape

The global pertussis vaccine market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are Sanofi, GlaxoSmithKline, Novartis AG, Seqirus, Merck Sharp & Dohme Corp., and Astellas Pharma US, Inc., KM Biologics

GlaxoSmithKline

Overview: GlaxoSmithKline is a science-led global healthcare company. It is the world's largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. The company was founded in 2000. It has headquarters in the United Kingdom.

Product Portfolio: The company's BOOSTRIX is a vaccine for active booster immunization against tetanus, diphtheria, and pertussis in people aged 10 and up. It is available as single-dose vials and prefilled syringes with a 0.5-mL injection suspension.

Key Development: On 23rd June 2021, The new GSK prioritized R&D and commercial investment in Vaccines and Specialty Medicines, which are expected to account for roughly three-quarters of company sales by 2026.

Why Purchase the Report?

Visualize the composition of the global pertussis vaccine market segmentation by product type, by vaccine type, and end user highlighting the key commercial assets and players.

Identify commercial opportunities in global pertussis vaccine market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global pertussis vaccine market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pertussis vaccine market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Pertussis Vaccine Market- By Product Type

DTaP vaccine

Daptacel

Infanrix

Kinrix

Pediarix

Pentacel

Quaracel

Tdap vaccine

Boostrix

Adacel

Global Pertussis Vaccine Market- By Vaccine Type

Whole-cell vaccine

Acellular vaccine

Global Pertussis Vaccine Market- By End User

Hospitals

Clinics

Vaccination Centers

Other

Global Pertussis Vaccine Market- By Region

North America

Europe

South America

Asia Pacific

Middle East and Africa

Table of Contents

1. Global Pertussis Vaccine MarketMethodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Pertussis Vaccine Market- Market Definition and Overview

3. Global Pertussis Vaccine Market- Executive Summary

  • 3.1. Market Snippet By Product Type
  • 3.2. Market Snippet By Vaccine Type
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet By Region

4. Global Pertussis Vaccine Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The adoption of pertussis vaccination
    • 4.1.2. Restraints:
      • 4.1.2.1. The side effects associated with pertussis vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Pertussis Vaccine Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Global Pertussis Vaccine Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Pertussis Vaccine Market- By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 7.3. Market Attractiveness Index, By Product Type
    • 7.3.1. DTaP vaccine*
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
      • 7.3.1.1.3. Daptacel
      • 7.3.1.1.4. Infanrix
      • 7.3.1.1.5. Kinrix
      • 7.3.1.1.6. Pediarix
      • 7.3.1.1.7. Pentacel
      • 7.3.1.1.8. Quaracel
    • 7.3.2. Tdap vaccine
      • 7.3.2.1. Boostrix
      • 7.3.2.2. Adacel

8. Global Pertussis Vaccine Market- By Vaccine Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 8.3. Market Attractiveness Index, By Vaccine Type
    • 8.3.1. Whole-cell vaccine
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 8.3.2. Acellular vaccine

9. Global Pertussis Vaccine Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Vaccination Centers
  • 9.5. Other

10. Global Pertussis Vaccine Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.5.1. U.S.
      • 10.2.5.2. Canada
      • 10.2.5.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.5.1. Brazil
      • 10.4.5.2. Argentina
      • 10.4.5.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.5.1. China
      • 10.5.5.2. India
      • 10.5.5.3. Japan
      • 10.5.5.4. Australia
      • 10.5.5.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Pertussis Vaccine Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Pertussis Vaccine Market- Company Profiles

  • 12.1. GlaxoSmithKline*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi
  • 12.3. Novartis AG
  • 12.4. Seqirus
  • 12.5. Merck Sharp & Dohme Corp
  • 12.6. Astellas Pharma US, Inc.
  • 12.7. KM Biologics

LIST NOT EXHAUSTIVE

13. Global Pertussis Vaccine Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us